Your Shopping Cart Is Empty
| Report Code: A03790 | Sep 2017 | Pages: 174 | ||
| Tables: 56 | Charts: 54 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Lamea Ivd Market
Request Now !The LAMEA IVD Market accounted for $7,413 million in 2016, and is estimated to reach $10,316 million by 2023, growing at a CAGR of 4.7% from 2017 to 2023. In vitro diagnostics (IVD) are the medical diagnostic devices and reagents used to examine the body specimens for detection of diseases, infections, and chronic conditions and identify appropriate treatments.
Technological advancements in the field of personalized medicine and companion diagnostics drive the LAMEA IVD market. In addition, increase in prevalence of chronic diseases, infectious diseases, and lifestyle-related conditions such as diabetes, hypertension, and others, and rise in geriatric population fuel the growth of the IVD market. Furthermore, growth in investment in healthcare sector by government and private companies is anticipated to boost the market growth. However, unfavorable reimbursement policies and stringent government regulations associated with manufacturing and sale of IVD are expected to hamper the market. Ongoing R&D activities related to IVD are anticipated to present new opportunities for the market. Moreover, the LAMEA region offers lucrative growth opportunities to the IVD market players owing to the increase in awareness of preventive healthcare measures and decentralized universal healthcare access.
LAMEA IVD Market Segmentation
Segment Review
Based on product type, the market is categorized into reagents, instruments, and software & services. The reagent segment accounted for the highest market share in 2016, and the software and services is expected to grow at the highest growth rate during the forecast period. The growth of the reagent market is attributed to the wide availability of effective and cost-efficient reagents. On the basis of technique, the immunodiagnostics segment captured the highest market share in 2016, owing to the increase in demand of personalized medicines. On the basis of application, infectious diseases segment captured the highest market share in 2016, due to rise in prevalence of infectious diseases and increase in preventive healthcare awareness among the population. Based on end users, the standalone laboratory segment captured the highest market share in 2016, primarily due increase in outsourcing of the lab test.
Top Investment Pocket
Country Wise Review
Country wise, it is analyzed across Latin America, Middle East, and Africa. Latin America accounted for the highest share of the market in 2016. Africa is anticipated to witness the highest growth rate during the forecast period. In addition, this region is expected to emerge as the area with maximum growth potential due to the focus of key players in the emerging economies.
Middle East IVD Market ($Million), 2017-2023
Increase in Prevalence of Chronic and Infectious Diseases
According to WHO, globally people living with HIV accounted for approximately 36.7 million in 2016, of which the highest number of people living with HIV is reported in Africa with approximately 25.6 million. According to WHO estimates, tuberculosis accounted for 450,000 cases in 2013, in the South African countries. Furthermore, it also stated that out of these 450,000 cases, approximately 270,000 (60%) people have both HIV and TB. The increase in these diseases is expected to increase the demand of the diagnostic devices, which in turn drives the IVD market.
Increase in Technological Advancements
Technology plays a vital role in the advancement of healthcare sector. Earlier, molecular testing was performed only by a skilled professional in laboratories and hospitals, however, the automated technology enables testing not only in hospitals but also at home. For instance, in 2017 BioSURE introduced first self-test HIV kit known as, BioSURE HIV Self-Test in South Africa. This overcomes the challenge of HIV diagnosis in South Africa, as the people did not have access to test facility or did not incline to test themselves. The escalation in rate of the technological advancement and increase in preventive awareness is expected to raise the demand for diagnosis, thereby driving the IVD market.
Increase in Government Expenditures on Healthcare
The need of cost reduction and continuous quality improvement in healthcare sector creates opportunity for investment. Hence, the governments of all the regions have increased their healthcare expenditures for reducing the disease rate in the countries. According to the WHO, the total healthcare expenditure for Nigerian government has increased from 6.48% in 2013 to 8.17% in 2014. The increase in LAMEA economic conditions are expected to increase government funding in healthcare sector, which in turn contributes to the growth of the IVD market.
Major companies operating in the market adopt product launch as their key development strategy. Companies profiled in this market include, Thermo Fisher Scientific Inc., Alere Inc., Biomerieux, Danaher Corporation, F. Hoffmann-La Roche AG, Becton Dickinson and Company, Bio-Rad Laboratories, Bayer AG, Sysmex Corporation, and Johnson & Johnson among others.
Key Benefits :
LAMEA IVD Market Report Highlights
| Aspects | Details |
|---|---|
| By Product Type |
|
| By TECHNIQUE |
|
| By APPLICATION |
|
| By END USERS |
|
| By Country |
|
| Key Market Players | DANAHER CORPORATION, F. HOFFMANN-LA ROCHE AG, SYSMEX CORPORATION, BIO-RAD LABORATORIES, BIOMERIEUX, BECTON DICKINSON AND COMPANY, THERMO FISHER SCIENTIFIC INC, ALERE INC, BAYER AG, JOHNSON & JOHNSON |
CHAPTER 1 INTRODUCTION
1.1 REPORT DESCRIPTION
1.2 KEY BENEFITS
1.3 KEY MARKET SEGMENTS
1.4 RESEARCH METHODOLOGY
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1 MARKET DEFINITION AND SCOPE
3.2 KEY FINDINGS
3.2.1 Top investment pockets
3.2.2 Top winning strategies
3.3 PORTER’S FIVE FORCES ANALYSIS
3.3.1 Bargaining power of suppliers
3.3.2 Bargaining power of buyers
3.3.3 Threat of new entrants
3.3.4 Threat of substitute
3.3.5 Competitive rivalry
3.4 MARKET SHARE ANALYSIS, 2016
3.5 MARKET DYNAMICS
3.5.1 Drivers
3.5.1.1 Increasing incidence of chronic and infectious diseases
3.5.1.2 Technological advancements in IVD
3.5.1.3 Emergence of minimal invasive technologies
3.5.1.4 Increasing government expenditures on healthcare
3.5.1.5 Increase in popularity of personalized medicine approach
3.5.2 Restraint
3.5.2.1 Unclear reimbursement policies
3.5.2.2 Stringent regulatory policies
3.5.3 Opportunity
3.5.3.1 Potential opportunities for outsourcing
3.5.3.2 Convergence of new technologies
CHAPTER 4 IVD MARKET, BY PRODUCT TYPE
4.1 OVERVIEW
4.1.1 Market size and forecast
4.2 REAGENTS
4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.3 INSTRUMENTS
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.4 SOFTWARE AND SERVICES
4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast
CHAPTER 5 IVD MARKET, BY TECHNIQUE
5.1 OVERVIEW
5.1.1 Market size and forecast
5.2 IMMUNODIAGNOSTICS
5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Market size and forecast
5.2.4 Enzyme-linked immunosorbent assay (ELISA)
5.2.4.1 Market size and forecast
5.2.4.2 Chemiluminescence immunoassay (CLIA)
5.2.4.2.1 Market size and forecast
5.2.4.3 Fluorescence immunoassay (FIA)
5.2.4.3.1 Market size and forecast
5.2.4.4 Colorimetric immunoassay (CI)
5.2.4.4.1 Market size and forecast
5.2.5 Rapid tests
5.2.5.1 Market size and forecast
5.2.6 Enzyme-linked immunospot (ELISPOT)
5.2.6.1 Market size and forecast
5.2.7 Radioimmunoassay (RIA)
5.2.7.1 Market size and forecast
5.2.8 Western blot
5.2.8.1 Market size and forecast
5.3 BLOOD TESTING
5.3.1 Key market trends
5.3.2 Key growth factors and opportunities
5.3.3 Market size and forecast
5.4 MOLECULAR DIAGNOSTICS
5.4.1 Key market trends
5.4.2 Key growth factors and opportunities
5.4.3 Market size and forecast
5.4.4 Polymerize chain reaction (PCR)
5.4.4.1 Market size and forecast
5.4.5 Isothermal nucleic acid technology (INAAT)
5.4.5.1 Market size and forecast
5.4.6 Hybridization
5.4.6.1 Market size and forecast
5.4.7 DNA diagnostics
5.4.7.1 Market size and forecast
5.4.8 Microarray
5.4.8.1 Market size and forecast
5.4.9 Others
5.4.9.1 Market size and forecast
5.5 TISSUE DIAGNOSTICS
5.5.1 Key market trends
5.5.2 Key growth factors and opportunities
5.5.3 Market size and forecast
5.6 CLINICAL CHEMISTRY
5.6.1 Key market trends
5.6.2 Key growth factors and opportunities
5.6.3 Market size and forecast
5.6.4 Basic metabolic panel
5.6.4.1 Market size and forecast
5.6.5 Liver panel
5.6.5.1 Market size and forecast
5.6.6 Renal profile
5.6.6.1 Market size and forecast
5.6.7 Lipid profile
5.6.7.1 Market size and forecast
5.6.8 Thyroid function panel
5.6.8.1 Market size and forecast
5.6.9 Electrolyte panel
5.6.9.1 Market size and forecast
5.6.10 Speciality chemicals
5.6.10.1 Market size and forecast
5.7 OTHER IVD TECHNIQUES
5.7.1 Key market trends
5.7.2 Key growth factors and opportunities
5.7.3 Market size and forecast
CHAPTER 6 IVD MARKET, BY APPLICATION
6.1 INFECTIOUS DISEASES
6.1.1 Key market trends
6.1.2 Key growth factors and opportunities
6.1.3 Market size and forecast
6.2 CANCER
6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast
6.3 CARDIAC DISEASES
6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Market size and forecast
6.4 IMMUNE SYSTEM DISORDERS
6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast
6.5 NEPHROLOGICAL DISEASES
6.5.1 Key market trends
6.5.2 Key growth factors and opportunities
6.5.3 Market size and forecast
6.6 GASTROINTESTINAL DISEASES
6.6.1 Key market trends
6.6.2 Key growth factors and opportunities
6.6.3 Market size and forecast
6.7 OTHERS INDICATIONS
6.7.1 Key market trends
6.7.2 Key growth factors and opportunities
6.7.3 Market size and forecast
CHAPTER 7 IVD MARKET BY END USERS
7.1 STANDALONE LABORATORIES
7.1.1 Market size and forecast
7.2 HOSPITALS
7.2.1 Key market trends
7.2.2 Key growth factors and opportunities
7.2.3 Market size and forecast
7.3 ACADEMIC AND MEDICAL SCHOOLS
7.3.1 Key market trends
7.3.2 Key growth factors and opportunities
7.3.3 Market size and forecast
7.4 POINT OF CARE TESTING
7.4.1 Key market trends
7.4.2 Key growth factors and opportunities
7.4.3 Market size and forecast
7.5 OTHERS END-USER
7.5.1 Key market trends
7.5.2 Key growth factors and opportunities
7.5.3 Market size and forecast
CHAPTER 8 LAMEA IVD MARKET
8.1 Key market trends
8.2 Key growth factors and opportunities
8.3 Market size and forecast
8.4 Latin America
8.4.1 Market size and forecast
8.5 Middle East
8.5.1 Market size and forecast
8.6 Africa
8.4.6.1 Market size and forecast
CHAPTER 9 COMPANY PROFILES
9.1 THERMO FISHER SCIENTIFIC INC.
9.1.1 Company overview
9.1.2 Business performance
9.1.3 Key strategies and development
9.2 ALERE INC.
9.2.1 Company overview
9.2.2 Business performance
9.2.3 Key strategies and developments
9.3 BIOMERIEUX
9.3.1 Company overview
9.3.2 Business performance
9.3.3 Key strategies and developments
9.4 DANAHER CORPORATION
9.4.1 Company overview
9.4.2 Business performance
9.4.3 Key strategies and development
9.5 F. HOFFMANN-LA ROCHE AG
9.5.1 Company overview
9.5.2 Business performance
9.5.3 Key strategies and developments
9.6 BECTON DICKINSON AND COMPANY
9.6.1 Company overview
9.6.2 Business performance
9.6.3 Key strategies and development
9.7 BIO-RAD LABORATORIES
9.7.1 Company overview
9.7.2 Business performance
9.7.3 Key strategies and developments
9.8 BAYER AG
9.8.1 Company overview
9.8.2 Business performance
9.8.3 Key strategies and development
9.9 SYSMEX CORPORATION
9.9.1 Company overview
9.9.2 Business performance
9.9.3 Key strategies and developments
9.10 JOHNSON & JOHNSON
9.10.1 Company overview
9.10.2 Business performance
9.10.3 Key strategies and development
List of Figures
FIGURE 1 MARKET SEGMENTATION
FIGURE 2 TOP INVESTMENT POCKETS
FIGURE 3 TOP WINNING STRATEGIES, 2014-2016 (%)
FIGURE 4 TOP WINNING STRATEGIES: NATURE AND TYPE, 2014-2016
FIGURE 5 PORTER’S FIVE FORCES ANALYSIS
FIGURE 6 MARKET SHARE ANALYSIS: IVD MARKET, 2016
FIGURE 7 LAMEA CHEMILUMINESCENCE IMMUNOASSAY (CLISA) MARKET, 2016-2023 ($MILLION)
FIGURE 8 LAMEA FLUORESCENCE IMMUNOASSAY (FIA) MARKET, 2016-2023 ($MILLION)
FIGURE 9 LAMEA COLORIMETRIC IMMUNOASSAY (CI) MARKET, 2016-2023 ($MILLION)
FIGURE 10 LAMEA RAPID TESTS MARKET, 2016-2023 ($MILLION)
FIGURE 11 LAMEA ENZYME-LINKED IMMUNOSPOT (ELISPOT) MARKET, 2016-2023 ($MILLION)
FIGURE 12 LAMEA RADIOIMMUNOASSAY (RIA) MARKET, 2016-2023 ($MILLION)
FIGURE 13 LAMEA WESTERN BLOT TECHNIQUE MARKET, 2016-2023 ($MILLION)
FIGURE 14 LAMEA POLYMERIZE CHAIN REACTION PCR MARKET, 2016-2023 ($MILLION)
FIGURE 15 LAMEA ISOTHERMAL NUCLEIC ACID TECHNOLOGY (INAAT) MARKET, 2016-2023 ($MILLION)
FIGURE 16 LAMEA HYBRIDIZATION MARKET, 2016-2023 ($MILLION)
FIGURE 17 LAMEA DNA DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 18 LAMEA MICROARRAY MARKET, 2016-2023 ($MILLION)
FIGURE 19 LAMEA OTHER MOLECULAR DIAGNOSTIC TECHNIQUE MARKET, 2016-2023 ($MILLION)
FIGURE 20 LAMEA BASIC METABOLIC PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 21 LAMEA LIVER PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 22 LAMEA RENAL PROFILE MARKET, 2016-2023 ($MILLION)
FIGURE 23 LAMEA LIPID PROFILE MARKET, 2016-2023 ($MILLION)
FIGURE 24 LAMEA THYROID FUNCTION PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 25 LAMEA ELECTROLYTE PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 26 LAMEA SPECIALITY CHEMICALS MARKET, 2016-2023 ($MILLION)
FIGURE 27 THERMO FISHER SCIENTIFIC INC.: REVENUE, 2014-2016, ($MILLION)
FIGURE 28 THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 29 THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 30 ALERE INC.: REVENUE, 2014-2016, ($MILLION)
FIGURE 31 ALERE INC.: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 32 ALERE INC.: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 33 BIOMERIEUX REVENUE: 2014-2016 ($MILLION)
FIGURE 34 BIOMERIEUX: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 35 BIOMERIEUX: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 36 DANAHER CORPORATION: REVENUE, 2014-2016 ($MILLION)
FIGURE 37 DANAHER CORPORATION: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 38 DANAHER CORPORATION: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 39 ROCHE DIAGNOSTICS: REVENUE, 2014-2016 ($MILLION)
FIGURE 40 ROCHE DIAGNOSTICS: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 41 BECTON, DICKINSON AND COMPANY: REVENUE, 2014-2016 ($MILLION)
FIGURE 42 BECTON DICKINSON AND COMPANY: REVENUES BY SEGMENT (%) (2016)
FIGURE 43 BECTON DICKINSON AND COMPANY: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 44 BIO-RAD LABORATORIES: REVENUE, 2014-2016 ($MILLION)
FIGURE 45 BIO RAD LABORATORIES, INC.: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 46 BIO RAD LABORATORIES, INC.: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 47 BAYER AG: REVENUE, 2014-2016 ($MILLION)
FIGURE 48 BAYER AG: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 49 SYSMEX CORPORATION: REVENUE, 2014-2016 ($MILLION)
FIGURE 50 SYSMEX CORPORATION: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 51 SYSMEX CORPORATION: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 52 JOHNSON & JOHSNON: REVENUE, 2014 - 2016 ($MILLION)
FIGURE 53 JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 54 JOHNSON & JOHNSON: REVENUE SHARE BY GEOGRAPHY, (%)(2016)
List of Tables
TABLE 1 INCIDENCE OF DISEASES
TABLE 2 LAMEA IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 3 LAMEA IVD REAGENTS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 4 LAMEA IVD INSTRUMENTS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 5 LAMEA IVD SOFTWARE & SERVICES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 6 LAMEA IVD MARKET BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 7 LAMEA IVD IMMUNODIAGNOSTIC TECHNIQUE MARKET, BY TYPES, 2016-2023 ($MILLION)
TABLE 8 LAMEA IVD IMMUNODIAGNOSTIC TECHNIQUE MARKET, BY COUNTRY,2016-2023 ($MILLION)
TABLE 9 LAMEA IVD IMMUNODIAGNOSTIC TECHNIQUE MARKET FOR ELISA, BY TYPES, 2016-2023 ($MILLION)
TABLE 10 LAMEA IVD BLOOD TESTING TECHNIQUE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 11 LAMEA IVD MOLECULAR DIAGNOSTICS TECHNIQUE MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 12 LAMEA IVD MOLECULAR DIAGNOSTICS TECHNIQUE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 13 LAMEA IVD TISSUE DIAGNOSTICS TECHNIQUE MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 14 LAMEA IVD CLINICAL CHEMISTRY TECHNIQUE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 15 LAMEA OTHER IVD TECHNIQUES MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 16 LAMEA IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 17 LAMEA IVD INFECTIOUS DISEASES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 18 LAMEA IVD CANCER MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 19 LAMEA IVD CARDIAC DISEASES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 20 LAMEA IVD IMMUNE SYSTEM DISORDER MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 21 LAMEA IVD NEPHROLOGICAL DISEASES MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 22 LAMEA IVD GASTROINTESTINAL DISEASES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 23 LAMEA IVD OTHER INDICATION MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 24 LAMEA IVD MARKET, BY END USER, 2016-2023, ($MILLION)
TABLE 25 LAMEA IVD STANDALONE LABORATORIES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 26 LAMEA IVD HOSPITALS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 27 LAMEA IVD ACADEMIC AND MEDICAL SCHOOLS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 28 LAMEA IVD POINT OF CARE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 29 LAMEA IVD OTHER END-USER MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 30 LAMEA IVD MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 31 LAMEA IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 32 LAMEA IVD MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 33 LAMEA IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 34 LAMEA IVD MARKET, BY END-USER, 2016-2023 ($MILLION)
TABLE 35 LATIN AMERICA IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 36 LATIN AMERICA IVD MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 37 LATIN AMERICA IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 38 LATIN AMERICA IVD MARKET, BY END-USER, 2016-2023 ($MILLION)
TABLE 39 MIDDLE EAST IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 40 MIDDLE EAST IVD MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 41 MIDDLE EAST IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 42 MIDDLE EAST IVD MARKET, BY END-USER, 2016-2023 ($MILLION)
TABLE 43 AFRICA IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 44 AFRICA IVD MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 45 AFRICA IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 46 AFRICA IVD MARKET, BY END-USER, 2016-2023 ($MILLION)
TABLE 47 THERMO FISHER SCIENTIFIC INC. COMPANY SNAPSHOT
TABLE 48 ALERE INC. COMPANY SNAPSHOT
TABLE 49 BIOMERIEUX COMPANY SNAPSHOT
TABLE 50 DANAHER CORPORATION COMPANY SNAPSHOT
TABLE 51 ROCHE DIAGNOSTICS COMPANY SNAPSHOT
TABLE 52 BECTON DICKINSON AND COMPANY SNAPSHOT
TABLE 53 BIO-RAD LABORATORIES, INC. COMAPNY SNAPSHOT
TABLE 54 BAYER AG COMPANY SNAPSHOT
TABLE 55 SYSMEX CORPORATION COMPANY SNAPSHOT
TABLE 56 JOHNSON & JOHNSON PVT LTD. COMPANY SNAPSHOT
In vitro diagnostics (IVD) are diagnostic tests that monitor the concentration of blood, urine, stool, tissues, and body fluids of human body and provide information to assist the diagnosis and treatment of diseases and disorders. These tests are generally performed in standalone laboratory, hospitals, academic and medical schools, point-of-care testing, and others. The standalone laboratories accounted for the highest market share in 2016 and is expected to dominate the market during the forecast period owing to the increase in the outsourcing of tests and availability of high-tech & well-equipped machines for the fast & accurate test results.
Latin America accounted for the highest share owing to improving healthcare infrastructure due to increase in government expenditure in healthcare sector. According to the WHO, the Mexico government healthcare expenditure has increased from 11.36% in 2011 to 11.58% in 2014. Africa accounted for the highest market potential because of rise in prevalence of communicable and non-communicable diseases such as tuberculosis, HIV, cancer, and others. In addition, private companies and government initiatives for the improvement of healthcare sector are expected to gain high growth opportunities in the market.
Major companies involved in the LAMEA IVD market are Thermo Fisher Scientific Inc., Alere Inc., Biomerieux, Danaher Corporation, F. Hoffmann-La Roche AG, Becton Dickinson and Company, Bio-Rad Laboratories, Bayer AG, Sysmex Corporation, and Johnson & Johnson among others.
Start reading instantly.
This Report and over 68,439+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report